ArticleIJID regions2025
Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEV
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- An active post-marketing surveillance study to evaluate the safety and immunogenicity of Zyvac TCV in healthy participants.Human vaccines & immunotherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Typhoid infections remain one of the major health concerns worldwide. Vaccines that prevent typhoid, particularly, the conjugated polysaccharide ones, are an important tool in addressing this major health concern. Here, we report on the safety profile of Biological E's TYPHIBEV Methods: This phase IV multicenter, open-label study enrolled 1252 healthy subjects aged 6 months to 45 years, stratified into three age subsets. In the 6 months to 2 years age group, 400 subjects aged 9-12 months were randomly allocated 1:1 to receive TYPHIBEV Results: TYPHIBEV Conclusions: No safety signals were identified during this study and no immunogenic inference was seen when TYPHIBEV was co-administered with MR. Trial registration: CTRI/2022/02/040285.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.